{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T10:59:27Z","timestamp":1760266767732},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2007,4,17]],"date-time":"2007-04-17T00:00:00Z","timestamp":1176768000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Women's Health"],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.1186\/1472-6874-7-6","type":"journal-article","created":{"date-parts":[[2007,4,30]],"date-time":"2007-04-30T15:53:17Z","timestamp":1177948397000},"source":"Crossref","is-referenced-by-count":22,"title":["Cost-effectiveness of preventative therapies for postmenopausal women with osteopenia"],"prefix":"10.1186","volume":"7","author":[{"given":"Eric S","family":"Meadows","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Klein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew D","family":"Rousculp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lee","family":"Smolen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert L","family":"Ohsfeldt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph A","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,4,17]]},"reference":[{"key":"102_CR1","first-page":"1","volume":"843","author":"World Health Organization (WHO Study Group)","year":"1994","unstructured":"World Health Organization (WHO Study Group): Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994, 843: 1-129.","journal-title":"World Health Organ Tech Rep Ser"},{"key":"102_CR2","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1359\/jbmr.1997.12.11.1761","volume":"12","author":"AC Looker","year":"1997","unstructured":"Looker AC, Orwoll ES, Johnston CC, Lindsay RL, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP: Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res. 1997, 12: 1761-1768. 10.1359\/jbmr.1997.12.11.1761.","journal-title":"J Bone Miner Res"},{"key":"102_CR3","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1001\/archinte.164.10.1108","volume":"164","author":"ES Siris","year":"2004","unstructured":"Siris ES, Chen YT, Abbott TA, Barrett-Connor E, Miller PD, Wehren LE, Berger ML: Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med. 2004, 164: 1108-1112. 10.1001\/archinte.164.10.1108.","journal-title":"Arch Intern Med"},{"key":"102_CR4","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1007\/s00198-006-0135-9","volume":"17","author":"JA Pasco","year":"2006","unstructured":"Pasco JA, Seeman E, Henry MJ, Merriman EN, Nicholson GC, Kotowicz MA: The population burden of fractures originates in women with osteopenia, not osteoporosis. Osteoporos Int. 2006, 17: 1404-1409. 10.1007\/s00198-006-0135-9.","journal-title":"Osteoporos Int"},{"key":"102_CR5","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.bone.2003.10.001","volume":"34","author":"SC Schuit","year":"2004","unstructured":"Schuit SC, van der KM, Weel AE, de Laet CE, Burger H, Seeman E, Hofman A, Uitterlinden AG, van Leeuwen JP, Pols HA: Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone. 2004, 34: 195-202. 10.1016\/j.bone.2003.10.001.","journal-title":"Bone"},{"key":"102_CR6","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1359\/jbmr.2003.18.11.1947","volume":"18","author":"KL Stone","year":"2003","unstructured":"Stone KL, Seeley DG, Lui LY, Cauley JA, Ensrud K, Browner WS, Nevitt MC, Cummings SR, Osteoporotic Fractures Research Group: BMD at multiple sites and risk of fracture of multiple types: long-term results from the Study of Osteoporotic Fractures. J Bone Miner Res. 2003, 18: 1947-1954. 10.1359\/jbmr.2003.18.11.1947.","journal-title":"J Bone Miner Res"},{"key":"102_CR7","doi-asserted-by":"publisher","first-page":"544","DOI":"10.4158\/EP.9.6.544","volume":"9","author":"SF Hodgson","year":"2003","unstructured":"Hodgson SF, Watts NB, Bilezikian JP, Clarke BL, Gray TK, Harris DW, Johnston CC, Kleerekoper M, Lindsay R, Luckey MM, McClung MR, Nankin HR, Petak SM, Recker RR, Anderson RJ, Bergman DA, Bloomgarden ZT, Dickey RA, Palumbo PJ, Peters AL, Rettinger HI, Rodbard HW, Rubenstein HA, AACE Osteoporosis TF: American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003.[erratum appears in Endocr Pract. 2004 Jan-Feb;10(1):90]. Endocr Pract. 2003, 9: 544-564.","journal-title":"Endocr Pract"},{"key":"102_CR8","volume-title":"Physician's guide to prevention and treatment of osteoporosis","author":"National Osteoporosis Foundation","year":"2003","unstructured":"National Osteoporosis Foundation: Physician's guide to prevention and treatment of osteoporosis. 2003, Washington, DC: NOF"},{"key":"102_CR9","first-page":"84","volume":"9","author":"North American Menopause Society","year":"2002","unstructured":"North American Menopause Society: Management of postmenopausal osteoporosis: position statement of the North American Menopause Society. Menopause. 2002, 9: 84-101.","journal-title":"Menopause"},{"key":"102_CR10","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1196\/annals.1346.041","volume":"1068","author":"RG Russell","year":"2006","unstructured":"Russell RG: Bisphosphonates: from bench to bedside. Ann NY Acad Sci. 2006, 1068: 367-401. 10.1196\/annals.1346.041.","journal-title":"Ann NY Acad Sci"},{"key":"102_CR11","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1196\/annals.1290.040","volume":"997","author":"MW Draper","year":"2003","unstructured":"Draper MW: The role of selective estrogen receptor modulators (SERMs) in postmenopausal health. Ann NY Acad Sci. 2003, 997: 373-377. 10.1196\/annals.1290.040.","journal-title":"Ann NY Acad Sci"},{"key":"102_CR12","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1001\/jama.281.23.2189","volume":"281","author":"SR Cummings","year":"1999","unstructured":"Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC: The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation.[erratum appears in JAMA 1999 Dec 8;282(22):2124]. JAMA. 1999, 281: 2189-2197. 10.1001\/jama.281.23.2189.","journal-title":"JAMA"},{"key":"102_CR13","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1001\/jama.282.7.637","volume":"282","author":"B Ettinger","year":"1999","unstructured":"Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud K, Avioli LV, Lips P, Cummings SR: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. JAMA. 1999, 282: 637-645. 10.1001\/jama.282.7.637.","journal-title":"JAMA"},{"key":"102_CR14","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1001\/jama.295.23.joc60074","volume":"295","author":"V Vogel","year":"2006","unstructured":"Vogel V, Costantino J, Wickerham D, Cronin W, Cecchini R, Atkins J, Bevers T, Fehrenbacher L, Pajon E, Wade J, Robidoux A, Margolese R, James J, Lippman SM, Runowicz C, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N, for the National Surgical Adjuvant Breast and Bowel Project (NSABP): Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial. JAMA. 2006, 295: 2727-2741. 10.1001\/jama.295.23.joc60074.","journal-title":"JAMA"},{"key":"102_CR15","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1097\/01.AOG.0000137349.79204.b8","volume":"104","author":"D Grady","year":"2004","unstructured":"Grady D, Ettinger B, Moscarelli E, Plouffe L, Sarkar S, Ciaccia A, Cummings S, for the Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators: Safety and Adverse Effects Associated with Raloxifene: Multiple Outcomes of Raloxifene Evaluation. Obstet Gynecol. 2004, 104: 837-844.","journal-title":"Obstet Gynecol"},{"key":"102_CR16","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1185\/030079905X61839","volume":"21","author":"S Martino","year":"2005","unstructured":"Martino S, Disch D, Dowsett SA, keech CA, Mershon J: Safety assessment of raloxifene over eight years in a clinical trial setting. Curr Med Res Opin. 2005, 21: 1441-1452. 10.1185\/030079905X61839.","journal-title":"Curr Med Res Opin"},{"key":"102_CR17","doi-asserted-by":"publisher","first-page":"734","DOI":"10.7326\/0003-4819-142-9-200505030-00008","volume":"142","author":"JT Schousboe","year":"2005","unstructured":"Schousboe JT, Nyman JA, Kane RL, Ensrud KE: Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women. Ann Intern Med. 2005, 142: 734-741.","journal-title":"Ann Intern Med"},{"key":"102_CR18","unstructured":"Vital Statistics of the United States: Mortality. [ http:\/\/www.cdc.gov\/nchs\/data\/dvs\/mortfinal2002_workipt1.pdf ]"},{"key":"102_CR19","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1007\/PL00020934","volume":"8","author":"National Osteoporosis Foundation","year":"1998","unstructured":"National Osteoporosis Foundation: Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis. Osteoporos Int. 1998, 8: S1-S80. 10.1007\/s001980050040.","journal-title":"Osteoporos Int"},{"key":"102_CR20","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/BF01623271","volume":"3","author":"LJ Melton III","year":"1993","unstructured":"Melton LJ, Lane AW, Cooper C, Eastell R, O'Fallon WM, Riggs BL: Prevalence and incidence of vertebral deformities. Osteoporos Int. 1993, 3: 113-119. 10.1007\/BF01623271.","journal-title":"Osteoporos Int"},{"key":"102_CR21","volume-title":"Health Technol Assess","author":"M Stevenson","year":"2005","unstructured":"Stevenson M, Lloyd Jones M, De Nigris E, Brewer N, Davis S, Oakley J: A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess. 2005, 9."},{"key":"102_CR22","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/S8756-3282(03)00061-9","volume":"32","author":"JA Kanis","year":"2003","unstructured":"Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B, Oglesby AK: The components of excess mortality after hip fracture. Bone. 2003, 32: 468-473. 10.1016\/S8756-3282(03)00061-9.","journal-title":"Bone"},{"key":"102_CR23","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S8756-3282(03)00200-X","volume":"33","author":"JA Kanis","year":"2003","unstructured":"Kanis JA, Johnell O, Black DM, Downs RW, Sarkar S, Fuerst T, Secrest RJ, Pavo I: Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial. Bone. 2003, 33: 293-300. 10.1016\/S8756-3282(03)00200-X.","journal-title":"Bone"},{"key":"102_CR24","first-page":"349","volume":"80","author":"SA Quandt","year":"2005","unstructured":"Quandt SA, Thompson DE, Schneider DL, Nevitt MC, Black DM, Fracture Intervention Trial Research Group: Effect of alendronate on vertebral fracture risk in women with bone mineral density T scores of-1.6 to -2.5 at the femoral neck: the Fracture Intervention Trial. Mayo Clin Proc. 2005, 80: 349.","journal-title":"Mayo Clin Proc"},{"key":"102_CR25","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","volume":"280","author":"SR Cummings","year":"1998","unstructured":"Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ: Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998, 280: 2077-2082. 10.1001\/jama.280.24.2077.","journal-title":"JAMA"},{"key":"102_CR26","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.4065\/80.9.1236","volume":"80","author":"N Mikhail","year":"2005","unstructured":"Mikhail N, Cope D: Alendronate and vertebral fracture risk.[comment, see author reply]. Mayo Clin Proc. 2005, 80: 1236.","journal-title":"Mayo Clin Proc"},{"key":"102_CR27","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.4065\/80.9.1236-a","volume":"80","author":"E Seeman","year":"2005","unstructured":"Seeman E: Alendronate and vertebral fracture risk.[comment, see author reply]. Mayo Clin Proc. 2005, 80: 1236.","journal-title":"Mayo Clin Proc"},{"key":"102_CR28","unstructured":"SEER 13 Registries for 2000\u20132002. Probability of Developing Cancer Breast Cancer by Race. [ http:\/\/canques.seer.cancer.gov ]"},{"key":"102_CR29","unstructured":"National Center for Chronic Disease Prevention and Health Promotion. National Breast and Cervical Cancer Early Detection Program. Breast Cancer Stage at Time of Diagnosis. [ http:\/\/www.cdc.gov\/cancer\/nbccedp\/bccpdfs\/national_report.pdf ]"},{"key":"102_CR30","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1023\/A:1006478317173","volume":"65","author":"J Cauley","year":"2001","unstructured":"Cauley J, Norton L, Lippman ME, Eckert S, Krueger KA, Purdie DW, Farrerons J, Karasik A, Mellstrom D, Ng KW, Stepan JJ, Powles TJ, Morrow M, Costa A, Silfen SL, Walls EL, Schmitt H, Muchmore DB, Jordan VC: Continued Breast Cancer Risk Reduction in Postmenopausal Women Treated with Raloxifene: 4-year Results from the MORE Trial. Breast Cancer Res Treat. 2001, 65: 125-134. 10.1023\/A:1006478317173.","journal-title":"Breast Cancer Res Treat"},{"key":"102_CR31","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1001\/archinte.158.6.585","volume":"158","author":"MD Silverstein","year":"1998","unstructured":"Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ: Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med. 1998, 158: 585-593. 10.1001\/archinte.158.6.585.","journal-title":"Arch Intern Med"},{"key":"102_CR32","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.amjmed.2004.01.018","volume":"117","author":"M Cushman","year":"2004","unstructured":"Cushman M, Tsai AW, White RH, Heckbert SR, Rosamond WD, Enright P, Folsom AR: Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med. 2004, 117: 19-25. 10.1016\/j.amjmed.2004.01.018.","journal-title":"Am J Med"},{"key":"102_CR33","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1001\/archinte.160.6.761","volume":"160","author":"JA Heit","year":"2000","unstructured":"Heit JA, Mohr DN, Silverstein MD, Petterson TM, O'Fallon WM, Melton LJ: Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med. 2000, 160: 761-768. 10.1001\/archinte.160.6.761.","journal-title":"Arch Intern Med"},{"key":"102_CR34","unstructured":"Drug average wholesale price. [ http:\/\/www.analysource.com ]"},{"key":"102_CR35","doi-asserted-by":"publisher","first-page":"3160","DOI":"10.1001\/archinte.160.20.3160","volume":"160","author":"G de Lissovoy","year":"2000","unstructured":"de Lissovoy G, Yusen RD, Spiro TE, Krupski WC, Champion AH, Sorensen SV: Cost for inpatient care of venous thrombosis: a trial of enoxaparin vs standard heparin. Arch Intern Med. 2000, 160: 3160-3165. 10.1001\/archinte.160.20.3160.","journal-title":"Arch Intern Med"},{"key":"102_CR36","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s001980200033","volume":"13","author":"SE Gabriel","year":"2002","unstructured":"Gabriel SE, Tosteson AN, Leibson CL, Crowson CS, Pond GR, Hammond CS, Melton LJ: Direct medical costs attributable to osteoporotic fractures. Osteoporos Int. 2002, 13: 323-330. 10.1007\/s001980200033.","journal-title":"Osteoporos Int"},{"key":"102_CR37","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/j.1524-4733.2005.04026.x","volume":"8","author":"KK Knight","year":"2005","unstructured":"Knight KK, Wong J, Hauch O, Wygant G, Aguilar D, Ofman JJ: Economic and utilization outcomes associated with choice of treatment for venous thromboembolism in hospitalized patients. Value Health. 2005, 8: 191-200. 10.1111\/j.1524-4733.2005.04026.x.","journal-title":"Value Health"},{"key":"102_CR38","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1001\/archinte.1996.00440180055007","volume":"156","author":"AP Legorreta","year":"1996","unstructured":"Legorreta AP, Brooks RJ, Leibowitz AN, Solin LJ: Cost of breast cancer treatment. A 4-year longitudinal study. Arch Intern Med. 1996, 156: 2197-2201. 10.1001\/archinte.156.19.2197.","journal-title":"Arch Intern Med"},{"key":"102_CR39","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1046\/j.1532-5415.2002.50455.x","volume":"50","author":"CL Leibson","year":"2002","unstructured":"Leibson CL, Tosteson AN, Gabriel SE, Ransom JE, Melton LJ: Mortality, disability, and nursing home use for persons with and without hip fracture: a population-based study. J Am Geriatr Soc. 2002, 50: 1644-1650. 10.1046\/j.1532-5415.2002.50455.x.","journal-title":"J Am Geriatr Soc"},{"key":"102_CR40","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s00198-005-1943-z","volume":"17","author":"RL Fleurence","year":"2006","unstructured":"Fleurence RL, Iglesias CP, Torgerson DJ: Economic evaluations of interventions for the prevention and treatment of osteoporosis: a structured review of the literature. Osteoporos Int. 2006, 17: 29-40. 10.1007\/s00198-005-1943-z.","journal-title":"Osteoporos Int"},{"key":"102_CR41","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/S0029-7844(01)01624-6","volume":"98","author":"K Armstrong","year":"2001","unstructured":"Armstrong K, Chen TM, Albert D, Randall TC, Schwartz JS: Cost-effectiveness of raloxifene and hormone replacement therapy in postmenopausal women: impact of breast cancer risk. Obstet Gynecol. 2001, 98: 996-1003. 10.1016\/S0029-7844(01)01624-6.","journal-title":"Obstet Gynecol"},{"key":"102_CR42","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1001\/archinte.159.13.1458","volume":"159","author":"NF Col","year":"1999","unstructured":"Col NF, Pauker SG, Goldberg RJ, Eckman MH, Orr RK, Ross EM, Wong JB: Individualizing therapy to prevent long-term consequences of estrogen deficiency in postmenopausal women. Arch Intern Med. 1999, 159: 1458-1466. 10.1001\/archinte.159.13.1458.","journal-title":"Arch Intern Med"},{"key":"102_CR43","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1185\/030079906X115568","volume":"22","author":"R Goeree","year":"2006","unstructured":"Goeree R, Blackhouse G, Adachi J: Cost-effectiveness of alternative treatments for women with osteoporosis in Canada. Curr Med Res Opin. 2006, 22: 1425-1436. 10.1185\/030079906X115568.","journal-title":"Curr Med Res Opin"},{"key":"102_CR44","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00198-004-1688-0","volume":"16","author":"JA Kanis","year":"2005","unstructured":"Kanis JA, Borgstrom F, Johnell O, Oden A, Sykes D, Jonsson B: Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporos Int. 2005, 16: 15-25. 10.1007\/s00198-004-1688-0.","journal-title":"Osteoporos Int"},{"key":"102_CR45","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1177\/0272989X06286478","volume":"26","author":"LR Mobley","year":"2006","unstructured":"Mobley LR, Hoerger TJ, Wittenborn JS, Galuska DA, Rao JK: Cost-effectiveness of osteoporosis screening and treatment with hormone replacement therapy, raloxifene, or alendronate. Med Decis Making. 2006, 26: 194-206. 10.1177\/0272989X06286478.","journal-title":"Med Decis Making"},{"key":"102_CR46","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1093\/jnci\/81.24.1879","volume":"81","author":"MH Gail","year":"1989","unstructured":"Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, Mulvihill JJ: Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989, 81: 1879-1886. 10.1093\/jnci\/81.24.1879.","journal-title":"J Natl Cancer Inst"},{"key":"102_CR47","doi-asserted-by":"crossref","first-page":"150","DOI":"10.18553\/jmcp.2003.9.2.150","volume":"9","author":"CD Mullins","year":"2003","unstructured":"Mullins CD, Ohsfeldt RL: Modeling the annual costs of postmenopausal prevention therapy: raloxifene, alendronate, or estrogen-progestin therapy. J Manag Care Pharm. 2003, 9: 150-158.","journal-title":"J Manag Care Pharm"},{"key":"102_CR48","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1001\/jama.288.3.321","volume":"288","author":"JE Rossouw","year":"2002","unstructured":"Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J, Writing Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002, 288: 321-333. 10.1001\/jama.288.3.321.","journal-title":"JAMA"},{"key":"102_CR49","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1093\/jnci\/93.5.358","volume":"93","author":"B Rockhill","year":"2001","unstructured":"Rockhill B, Spiegelman D, Byrne C, Hunter DJ, Colditz GA: Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst. 2001, 93: 358-366. 10.1093\/jnci\/93.5.358.","journal-title":"J Natl Cancer Inst"},{"key":"102_CR50","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa062462","volume":"355","author":"E Barrett-Connor","year":"2006","unstructured":"Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, McNabb MA, Wenger NK, Raloxifene Use for The Heart (RUTH) Trial Investigators: Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006, 355: 125-137. 10.1056\/NEJMoa062462.","journal-title":"N Engl J Med"},{"key":"102_CR51","doi-asserted-by":"publisher","first-page":"753","DOI":"10.7326\/0003-4819-144-10-200605160-00009","volume":"144","author":"SB Woo","year":"2006","unstructured":"Woo SB, Hellstein JW, Kalmar JR: Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006, 144: 753-761.","journal-title":"Ann Intern Med"},{"key":"102_CR52","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","volume":"90","author":"B Fisher","year":"1998","unstructured":"Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998, 90: 1371-1388. 10.1093\/jnci\/90.18.1371.","journal-title":"J Natl Cancer Inst"},{"key":"102_CR53","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1097\/01.AOG.0000133481.74113.f3","volume":"104","author":"S Cykert","year":"2004","unstructured":"Cykert S, Phifer N, Hansen C: Tamoxifen for breast cancer prevention: a framework for clinical decisions. Obstet Gynecol. 2004, 104: 433-442.","journal-title":"Obstet Gynecol"},{"key":"102_CR54","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s001980200069","volume":"13","author":"JA Kanis","year":"2002","unstructured":"Kanis JA, Black D, Cooper C, Dargent P, Dawson-Hughes B, De Laet C, Delmas P, Eisman J, Johnell O, Jonsson B, Melton L, Oden A, Papapoulos S, Pols H, Rizzoli R, Silman A, Tenenhouse A, International Osteoporosis Foundation, National Osteoporosis Foundation: A new approach to the development of assessment guidelines for osteoporosis. Osteoporos Int. 2002, 13: 527-536. 10.1007\/s001980200069.","journal-title":"Osteoporos Int"},{"key":"102_CR55","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1097\/00005650-200302000-00004","volume":"41","author":"S Macran","year":"2003","unstructured":"Macran S, Weatherly H, Kind P: Measuring population health: a comparison of three generic health status measures. Med Care. 2003, 41: 218-231. 10.1097\/00005650-200302000-00004.","journal-title":"Med Care"},{"key":"102_CR56","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s00198-003-1463-7","volume":"15","author":"JA Kanis","year":"2004","unstructured":"Kanis JA, Johnell O, Oden A, Borgstrom F, Zethraeus N, De Laet C, Jonsson B: The risk and burden of vertebral fractures in Sweden. Osteoporos Int. 2004, 15: 20-26. 10.1007\/s00198-003-1463-7.","journal-title":"Osteoporos Int"},{"key":"102_CR57","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1359\/jbmr.2000.15.7.1384","volume":"15","author":"A Oleksik","year":"2000","unstructured":"Oleksik A, Lips P, Dawson A, Minshall ME, Shen W, Cooper C, Kanis J: Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. J Bone Miner Res. 2000, 15: 1384-1392. 10.1359\/jbmr.2000.15.7.1384.","journal-title":"J Bone Miner Res"},{"key":"102_CR58","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.2165\/00019053-200119110-00003","volume":"19","author":"RE Brown","year":"2001","unstructured":"Brown RE, Hutton J, Burrell A: Cost effectiveness of treatment options in advanced breast cancer in the UK. Pharmacoeconomics. 2001, 19: 1091-1102. 10.2165\/00019053-200119110-00003.","journal-title":"Pharmacoeconomics"},{"key":"102_CR59","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1097\/00001813-199811000-00009","volume":"9","author":"RE Brown","year":"1998","unstructured":"Brown RE, Hutton J: Cost-utility model comparing docetaxel and paclitaxel in advanced breast cancer patients. Anticancer Drugs. 1998, 9: 899-907. 10.1097\/00001813-199811000-00009.","journal-title":"Anticancer Drugs"},{"key":"102_CR60","doi-asserted-by":"publisher","first-page":"504","DOI":"10.2165\/00019053-199610050-00008","volume":"10","author":"R Launois","year":"1996","unstructured":"Launois R, Reboul-Marty J, Henry B, Bonneterre J: A cost-utility analysis of second-line chemotherapy in metastatic breast cancer. Docetaxel versus paclitaxel versus vinorelbine. Pharmacoeconomics. 1996, 10: 504-521.","journal-title":"Pharmacoeconomics"},{"key":"102_CR61","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1023\/A:1005804101106","volume":"45","author":"J Norum","year":"1997","unstructured":"Norum J, Olsen JA, Wist EA: Lumpectomy or mastectomy? Is breast conserving surgery too expensive?. Breast Cancer Res Treat. 1997, 45: 7-14. 10.1023\/A:1005804101106.","journal-title":"Breast Cancer Res Treat"}],"container-title":["BMC Women's Health"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1472-6874-7-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6874-7-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6874-7-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6874-7-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T00:27:21Z","timestamp":1628814441000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcwomenshealth.biomedcentral.com\/articles\/10.1186\/1472-6874-7-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4,17]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["102"],"URL":"https:\/\/doi.org\/10.1186\/1472-6874-7-6","relation":{},"ISSN":["1472-6874"],"issn-type":[{"value":"1472-6874","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,4,17]]},"article-number":"6"}}